Diabetes Drug Liraglutide Reduces Bone Marrow Fat by Regulating the miR-150-5p/GDF11 Pathway
The GLP-1 agonist liraglutide reduces excess fat accumulation in bone marrow of diabetic rats by suppressing miR-150-5p and upregulating GDF11, revealing a novel bone-protective mechanism beyond blood sugar control.
Quick Facts
What This Study Found
Liraglutide reduces bone marrow fat accumulation in diabetic rats by suppressing miR-150-5p expression, which upregulates GDF11 — a novel mechanism explaining the peptide drug's bone-protective effects.
Key Numbers
HFD + STZ diabetic rat model; liraglutide treatment; miR-150-5p and GDF11 identified as key pathway mediators.
How They Did This
Diabetic rat model (HFD + STZ). High-throughput miRNA sequencing of BMSCs after liraglutide treatment identified differentially expressed miRNAs. Validated miR-150-5p/GDF11 axis using overexpression/knockdown studies in vitro (high-glucose BMSCs) and agomiR injection in vivo. Assessed bone marrow lipid accumulation histologically.
Why This Research Matters
Diabetes significantly increases fracture risk, partly through excess bone marrow fat replacing healthy bone-forming tissue. Discovering that liraglutide — already widely prescribed for diabetes — protects bone marrow through a specific molecular pathway adds another reason to consider GLP-1 agonists for diabetic patients at risk of bone disease.
The Bigger Picture
GLP-1 agonists continue to reveal benefits beyond glucose control — cardiovascular protection, weight loss, kidney protection, and now bone marrow fat reduction. This study adds mechanistic depth by identifying the miR-150-5p/GDF11 axis, suggesting that GLP-1 signaling influences epigenetic regulators (microRNAs) that control stem cell fate decisions in bone marrow. This could inform development of targeted therapies for diabetic bone disease.
What This Study Doesn't Tell Us
Animal study — human bone marrow response may differ. The HFD+STZ rat model is a simplified version of human type 2 diabetes. Only miR-150-5p was deeply characterized among the five changed miRNAs — the others may contribute. The study focused on adipogenesis but didn't assess bone density or fracture outcomes. Liraglutide dosing in rats may not correspond to human doses.
Questions This Raises
- ?Does liraglutide's bone marrow fat reduction translate to reduced fracture risk in diabetic patients?
- ?Do other GLP-1 agonists (semaglutide, tirzepatide) show the same miR-150-5p/GDF11-mediated bone protection?
- ?Could targeting miR-150-5p directly provide bone protection without needing a GLP-1 agonist?
Trust & Context
- Key Stat:
- miR-150-5p/GDF11 axis newly identified molecular pathway through which liraglutide reduces bone marrow fat — suppressing the microRNA that targets GDF11, a key inhibitor of adipogenesis
- Evidence Grade:
- Preliminary — animal study with in vitro validation identifying a molecular mechanism. No human bone marrow or fracture data.
- Study Age:
- Published in 2024, adding to the growing evidence of GLP-1 agonist benefits beyond glycemic control.
- Original Title:
- Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.
- Published In:
- European journal of pharmacology, 978, 176793 (2024)
- Authors:
- Wang, Na(2), Lin, Zhe, Gao, Liu, Wang, Bin, Wei, Kangxu, Zhang, Menghan, Li, Yukun, Xue, Peng
- Database ID:
- RPEP-09480
Evidence Hierarchy
Frequently Asked Questions
Why does diabetes cause fat to build up in bone marrow?
In diabetes, high blood sugar and metabolic dysfunction cause bone marrow stem cells to turn into fat cells instead of bone-forming cells. This excess fat crowds out healthy bone tissue, weakening the skeleton and increasing fracture risk. It's one reason why people with type 2 diabetes have higher fracture rates despite sometimes having normal bone density measurements.
Could liraglutide help prevent fractures in people with diabetes?
This animal study shows liraglutide reduces bone marrow fat through a specific molecular pathway, which is encouraging. However, we don't yet know if this translates to fewer fractures in humans. Clinical studies are needed to confirm whether liraglutide's bone marrow effects meaningfully reduce fracture risk in diabetic patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09480APA
Wang, Na; Lin, Zhe; Gao, Liu; Wang, Bin; Wei, Kangxu; Zhang, Menghan; Li, Yukun; Xue, Peng. (2024). Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.. European journal of pharmacology, 978, 176793. https://doi.org/10.1016/j.ejphar.2024.176793
MLA
Wang, Na, et al. "Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.." European journal of pharmacology, 2024. https://doi.org/10.1016/j.ejphar.2024.176793
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ ..." RPEP-09480. Retrieved from https://rethinkpeptides.com/research/wang-2024-liraglutide-reduces-bone-marrow
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.